What diseases does Osimertinib treat
Osimertinib is a third-generation EGFR-TKI targeted drug mainly used for the treatment of EGFR mutation positive non-small cell lung cancer (NSCLC), including adjuvant therapy, systemic therapy for locally advanced and metastatic patients, especially for T790M resistant mutation patients.
1. Main indications
(1) Adjuvant therapy: Used for adult NSCLC patients with EGFR exon 19 deletion or exon 21 L858R mutation detected after tumor resection.
(2) Localized late stage treatment: suitable for stage III unresectable NSCLC patients who have not progressed after synchronous/sequential radiotherapy and chemotherapy (requiring EGFR mutation positivity).
(3) First line treatment for metastatic NSCLC: The preferred option for patients with EGFR sensitive mutations (19del/L858R).
(4) Post resistance treatment: Targeting metastatic NSCLC patients with T790M mutation after progression of EGFR-TKI therapy.
2. Combination therapy plan
(1) Used in combination with pemetrexed and platinum based chemotherapy as first-line treatment for EGFR mutation positive locally advanced/metastatic NSCLC.
3. Target features
(1) Specific inhibition of EGFR sensitive mutation (19del/L858R) and drug-resistant mutation (T790M), blocking the tumor cell proliferation signaling pathway.
Disclaimer：《What diseases does Osimertinib treat》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！